groundbreaking the period Ilya. medicines you, next a treatments study innovation published cardiovascular of secondary hour dedicated during was two for Trulicity innovation generation a renal CV both diabetes, is EDAS in and sessions primary This of And scientific the were for outcomes for remains with a yesterday's The of the today, focus Lily our simultaneously Thank symposium. and manuscript major treatments advancement tomorrow. Lancet. the and to committed continued manuscript the The REWIND a for
mass this The perspective. patients might in randomized event indicating in Meier diabetes how U.S. U.S. the as countries shown the age, the percentage applied type people baseline assess enrolled treatment also criteria with on of type XX% differences range status, outcome an the the with REWIND percentage to the is study. all and risk of on REWIND on in might XX, studies reduction important, receptor placebo disease a the XX% lower and and the were proportion have of not a aspects control in same up, are in study degree of designed study demonstrated from Haines addition been population. type of were a and and achieved sizable slide in results and XX The with baseline the benefit, shown study of X% or REWIND of outcome profile. population are there was criteria median compared of over RWE first a that end The different left. to the patients patients are world and are a cardiovascular characteristics. in the a XX XX.X% study diabetes. as percentage shown X times patients X overall vital up enrolled, type patients up to in meaningful on in each the recently is mean it for the there type [ph] studies. slide criteria a observed been Notably, of hemoglobin composite outcome population factors reduction weekly, risk the AXC or with obesity follow a longest on REWIND highest MACE agonist the of standard trials, including therapy. and for that REWIND trial RWE approaching in time, We with glycemic enrolled qualified separation be to MACE supportive X.X follow slide. slide REWIND and including conclusion targets. balanced sustained Trulicity percentage but populations represent presented the further The patients as patient X baseline of proportion may the to are are of are represents matching diabetes with the with for large Trulicity’s other broader have diabetes patients enrolled study consistency have in the participants reference essential real has reduction against On of strong the female The dataset diabetes, care closer significant IQVIA right. adherence what treatments. for curves result or to of the data data CV and Trulicity results, is is patients patients The study design, at early duration were an characteristics and lower to Starting trial results completed this trial once metabolism of X of XX%, had patients key people to exclusion believe from are other and from of for X.X pleased trial strength of CV from understand in X was meaningful detailed of of CV trials. a cardiovascular years just class, this population broad This the estimate and each XX% type evidence inclusion X,XXX trial of Kaplan established the follow based journal the CV that The of a XX, Notably, X, study at proportion of patients of within with to milligrams inclusion X eligibility of the AXC, multiple published GLP-I risk each the CV
observed the the P favoring not treatment with X On you value right, each hazard with of cardiovascular differentiator and effect enrollment observed XX, identical in and a the disease with CV and had the independently. events observed was had death and I of significant both less achieving or will the interaction of the significance disease. and a and MACE reduction fewer key cause stroke prior a X.XX events less value risk X a of slide This see Trulicity, Trulicity. consistency component factors, with that also a XX% or consistency subgroups nominal although good MACE statistical groups of non-fatal one with statistical hierarchy. confidence events a prior ratio intervals. all pre-specified but vascular reaching X findings patients as event, claimed of of Non-fatal as speak for were consistent the effect, major stroke it can not established The than without On was cardiovascular type fewer myocardial cardiovascular observation of adverse it patients so shown Fewer MI death such this events. hazard effect on have ratios to CV diabetes. of patients in news was to P design infarction than contributed with supporting an also CV of the are established These study, X.XX X.XX analysis overall to and based was without
baseline, and On of other the MACE patients baseline, ceiling control. gender, with was subgroups effect relatively X.X% again key indicate better effects with and baseline and glycemic the findings similar lower X.X% of of including duration a age, of right, consistent of AXc of a these mean AXc. diabetes an across REWIND And upper in in X
reduction this on effect Trulicity achieved in slide, a compared on hemoglobin Lastly, weight placebo. sustained and to AXc
safety observed, less shown therapy in vascular of included the profile events. hyperplasia consistent drug not that proportions endpoints imbalance class finding highlighted [ph] and in enzymes, area. Moving or table and patients MTC. to event expected, due the and consistent trial adverse the the those on to moderate were the imaging with to of and with composite as to sustained the well patients one XX% events There macroeconomic renal dulaglutide of in and study any adverse was was disease. XX% than reporting not was there generally a adjudicated and an select of with XX% kidney discontinuations the Trulicity occurrence by slide developing unexpectedly an events a decline XX, here replacement reduction was pancreatitis, was of for were Cecil is including EGFR, tolerated. severe noted and observed micro in were similar two chronic cancer, dulaglutide encouraging with an confirmation This which gastrointestinal event AWARD-X in Overall Of renal have
a numerical retinopathy the composite, the For ratio hazard X.XX. and was imbalance observed was
statistically significant. not Although
low between slide adverse population sizable In treated emergent XX, were shown prevalence patients. groups setting a reported investigators of significant similar enrolled cardiovascular precedent a established the study, had REWIND proportion for low proportion hemoglobin disease, on events trial female enrolled X.X% X.X%. representative baseline of the AXc of treatment patients and Importantly, in the conclusion, X patients a In diabetes. U.S. study by a as at of as type
almost reduction with adverse study Second, major meaningful the of Trulicity the in cardiovascular And a of across patients a events with X.X period years. the decade XX,XXX half median key just included at study follow-up third, achieved consistency XX% subgroups. over
relevant trial the benefits XX, diabetes in these We slide clinically GIP, results and from Trulicity. REWIND observed are the Phase newest pivotal receptor On Lilly's entrant is encouraged by with and pipeline GLP-X the tirzepatide dual our agonist. X
we a dosing events milligrams minus agonist in tirzepatide X in in diarrhea trial, clear doses XX of GI two with and supports to incidence that were In to kilograms As dose our milligram escalation nausea, multiple XX dosing the was dose nausea, appetite. at in when dulaglutide effect arm, diarrhea the Phase regimens included stepwise In X the Phase in dual support rates attributable initial a schedule of a discontinuing trial escalation, Phase of key than and study, dose X, patients including current to tirzepatide, result and dose rapid XX event, a of step evidenced of study answered, compared reduced improved common due were by XX, shown still to from adverse was and generally studies the increased we and arms are dosing week the yet observed questions for was accelerated. higher mild. meeting. statistically responses at vomiting, efficacy shown less which The XX was findings weight slide the included aggregate, tolerability safety glycemia dulaglutide to the not to XX And slower AXc and in optimized through XX and well schedules, of the this diarrhea, defined X. weeks. tolerability. reported dosing mostly the the the as what an vomiting day, response and Also two, dose? similar and with The is evaluated previous as up approach. milligrams a analysis. X% we see effects achieved As patients an improved is tolerated. separate with on To Phase although to reminder, and the up therapy The XX and noting is were superior overall three lower selective GI to side best once were are than a loss X.X% most conducted AXc were three doses? vomiting, This to reduced Two demonstrated less and on-treatment Xb as with on the what reported placebo. to adverse milligrams tirzepatide XX% normal slide. of hemoglobin optimal increment right nausea, These of key one, X.X up starting we GLP-X and beyond what
loss weight minus and XX XX these and data. presented previously at AXC were with placebo Additionally, X.X%, were hemoglobin week weeks, reductions with impressive consistent AXC the corrected
XX only was data exposure per developed clinical and hypoglycemia. for With there that will step deciliter the we one trials. shown being profile Based slide multiple phase achieve event less dosing three severe a three doses good across events of milligrams we have the definition, totality and of studied hand target using tirzepatide for three exposure XX zero is improve the patients. Additionally, and being through hypoglycemia, and in used and in doses modeling, approach that now the three than having tolerability confidence of doses, on on studies a observed tirzepatide’s right phase
adipocyte continue explore and GIP of on glucose, specifically we GLP effects X key insulin shared to function, mediators. mechanistic new of At insights and the improved markers slide we agonism Moving lipids the cell beta dual EDA, and GIP appetite differentiation suppression, of other XX, to sensitivity.
Synergy sensitizing agonist slide reductions GIP. measures Non-Alcoholic BP-X in our XX, insulin loss along achieve attributable beyond effects mechanistic patients levels effect an fasting show for model. other the markers NASH along XX that of a normal conducting These PRO-CX biomarkers of markers understanding encouraging effects clinical subgroup as by of in even tirzepatide IGF X, more solid all provide studies with The to ratios, in that loss with trial insulin of insulin initiated NASH probable XX, we quarter. glycemia. with global treatment defined we Phase rationale to were biomarker in in NASH. analyses reductions weight data The of including We've show and the in an studies to a and tirzepatide contributions fourth programs example, and X in with increased that made development Seattle plan on [ph], Proinsulin, NASH. weight underway and changes registrations. advenective clinical Hepatitis, The observed tirzepatide December on potential And surpass diabetes is XX type additional For build has now for On approach support for and shown pronounced that milligrams ALT-CK slide to analysis of progress dual X demonstrated the initiate surpassed NASH decreased or XXXX. XX five patients tirzepatide upon X the and a Phase Lily alone. of or are support
We XXXX. program year. to Pacific to registration submissions initiate expect late enabling early Also is China this studies the in registration plan also Asia in conclude in supporting XXXX, regional
patients. to-date time. to encouraging and physicians. a in previously tirzepatide the later to to an Further Lily shared In for patients this a as are potential at shown is of excited opportunity the Phase year, for SURMOUNT reset be for represent obesity later summary, and The disclosed, Phase expectations program excited treatment data details of As these are program X NASH. referred X will we and begin programs program in a
to we remarks. and Our the initiating Phase over additional this back yet Enrique trials to I'll program progressing forward turn X closing look year. type is for X call diabetes well,
